Modi, Yasha S.
Goduni, Lediana
Moini, Hadi
Gibson, Andrea
Boucher, Nick http://orcid.org/0000-0002-3657-575X
Lucas, Genevieve
Dhoot, Dilsher S. http://orcid.org/0000-0002-1619-452X
Funding for this research was provided by:
Regeneron Pharmaceuticals
Article History
Received: 3 February 2022
Revised: 14 March 2023
Accepted: 5 April 2023
First Online: 8 May 2023
Competing interests
: YSM is a consultant for Alimera, Allergan, Genentech, Théa, and Zeiss. LG has served on the Alimera Sciences Fellows Advisory Board. HM is a salaried employee of Regeneron Pharmaceuticals, Inc. AG was a salaried employee of Regeneron Pharmaceuticals, Inc., at the time these analyses were undertaken. NB is a salaried employee of Vestrum Health. GL was a salaried employee of Vestrum Health at the time these analyses were undertaken. DSD is a consultant for Regeneron Pharmaceuticals, Inc., Genentech, Novartis, Bayer, Allergan, Alimera, Eyepoint Pharmaceuticals, Santen, Allegro, and RegenX Bio.
: De-identified electronic medical records of patients with MO secondary to BRVO in the Vestrum Health treatment and outcomes database (Vestrum Health, Naperville, Illinois, USA) constitutes a limited data set in which all patient identifiers have been completely removed and site and clinician data pseudo-anonymised. On this basis, formal ethics approval is not required, and formal ethics approval was not obtained.